Medical Licensing (MD/DO) · Independent exam preparation
ABVLM Board Certification Examination: Free Preparation Guide Study Guide
Practise venous and lymphatic diagnosis, vascular-test interpretation, procedural safety, and treatment selection for the ABVLM Board Certification Examination.
By CertMedbry · Updated 18 October 2026
Learn to distinguish reflux from obstruction, interpret vascular tests, assess compression safety, and select treatment for venous thrombosis, ulceration, lymphatic disease, and vascular anomalies. These 60 selected concepts approximate the 2025-effective blueprint: 13 Basic science, 19 Diagnostic evaluation, 17 practice knowledge and skills, and 11 Clinical management. This guide is selective; the official ABVLM outline defines the full examination scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
This guide addresses the ABVLM Board Certification Examination used in the Interventionalist full-certification pathway. Non-Interventionalist full certification and the Physician in Training and Board Eligible recognition pathways also involve the cognitive examination. Physician in Training and Board Eligible recognition are not full certification. ABVLM states that progression between pathways does not require repeating a previously completed cognitive examination.
ABVLM — Eligibility and Fees · ABVLM%2BCandidate%2BHandbook%2BJanuary%2B2026.%2BV2.pdf
Which blueprint and domain weights apply?
The ABVLM Exam Content Outline Effective 2025 assigns Basic science 21%, Diagnostic evaluation 32%, Knowledge and skills integral to the practice of venous and lymphatic medicine 28%, and Clinical management 19%. The document has March 2024 report footers; those footers do not change its stated 2025 effective year. ABVLM's preparation page and Applicant FAQs connect the examination to this outline. The separately linked November 2016 summary is historical and uses a different allocation.
ABVLM Exam Content Outline Effective 2025 · ABVLM — Applicant FAQs · Venous & Lymphatic Medicine Certification Exam Content Summary — November 2016
How many questions are scored, how many are pretest items, and how long is the examination?
ABVLM's published 2027 calendar specifies a four-hour certification examination. That cycle-specific duration does not establish the total question count or the scored/pretest split, which remain unconfirmed here. A January 2026 revised Candidate Handbook is available and is newer than the December 2025 edition previously linked by the preparation page. Use the January revision together with the applicable cycle calendar and appointment instructions. The 20 accompanying learning questions do not represent the examination's length.
ABVLM Exam Calendar & Deadlines | Venous & Lymphatic Medicine · ABVLM%2BCandidate%2BHandbook%2BJanuary%2B2026.%2BV2.pdf · ABVLM Certification Candidate Handbook — Revised December 2025
How is the examination delivered, and is it adaptive?
The general Applicant FAQs describe Pearson VUE testing-centre delivery or remote proctoring through OnVUE. However, the published 2027 calendar specifically states that the examination is delivered at a traditional, in-person testing centre. For that cycle, follow the dated calendar's in-person arrangement; the general FAQ does not confirm current remote availability. Adaptive delivery is not established by these sources. Follow the cycle-specific authorisation and appointment instructions.
ABVLM — Applicant FAQs · ABVLM Exam Calendar & Deadlines | Venous & Lymphatic Medicine
Which item styles should candidates expect?
The cited issuer information does not establish a complete inventory of item styles. ABVLM states that paid applicants receive access to a practice examination to become familiar with its format and questions. This guide uses independent four-option, single-best-answer MCQs for learning; it does not reproduce the official interface or claim to simulate every official item style.
How is passing performance determined?
ABVLM describes criterion-referenced testing with psychometric review and equating between administrations. Passing performance reflects an established competence standard rather than a fixed proportion of candidates who must pass. The FAQs explain that the raw percentage needed can vary with examination difficulty. No numerical passing score is asserted here, and performance on these learning questions does not predict certification results.
Which physicians and jurisdictions does ABVLM identify?
The Applicant FAQs identify physicians licensed in the United States, its territories, and Canada as the eligible jurisdictional population. They also describe additional documentation and board-certification requirements for foreign medical graduates practising in the United States. Eligibility depends on the chosen pathway and current criteria; this physician specialty examination should not be confused with an RN, NP, or general medical licensure examination.
What dates are published for the 2027 cycle?
The published calendar lists application-system opening on December 1, 2026, application submission from January 15 to May 31, 2027, and Pearson VUE registration opening on February 17, 2027 for approved candidates. The examination window is August 1 to September 15, 2027, excluding Sundays at test centres. Results are scheduled for November 2027. Submit accommodation requests with the application as directed by the Candidate Handbook, and check the issuer's calendar for subsequent changes.
ABVLM Exam Calendar & Deadlines | Venous & Lymphatic Medicine · ABVLM%2BCandidate%2BHandbook%2BJanuary%2B2026.%2BV2.pdf
ABVLM awards physician specialty certification. Diplomate denotes certification status associated with the ABVLM Board Certification Examination; it is not a separately named examination or a general medical licence. This independent educational guide and its original drills are not official ABVLM examination items.
Outline used: ABVLM Exam Content Outline Effective 2025, with March 2024 report footers; currently linked by ABVLM's preparation page and Applicant FAQs as reviewed on 2026-10-09. Candidate Handbook revised December 2025. The workbook label 'ABVLM Diplomate' maps to the Board Certification Examination used in ABVLM's certification process; Diplomate is a certification designation, not a separately named examination. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Basic science21%
1.How does superficial venous anatomy guide reflux treatment?
The great and small saphenous veins belong to the superficial system, whereas named deep veins lie beneath the muscular fascia. Perforating veins cross that fascia and connect the systems. Junctional and tributary anatomy varies, so a visible varicosity does not identify its reflux source. Duplex mapping should establish the responsible pathway and deep-system status before treatment. Anatomical continuity matters because removing a tributary alone may leave a symptomatic refluxing trunk untreated.
Apply it
A patient has medial calf varices and a prominent vein near the knee. Map the great saphenous trunk, tributaries, perforators, and deep system before deciding whether treatment should target a trunk, tributary, or both.
Common pitfall: Do not equate the largest visible vein with the primary reflux source; size and surface appearance cannot replace an anatomical duplex map.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
2.Why does walking normally lower distal venous pressure?
Calf contraction expels blood from deep veins, while competent valves limit retrograde refilling. Repeated steps therefore lower distal venous pressure from its standing level. Reflux, outflow obstruction, restricted ankle motion, or weak muscle activity can impair this pressure reduction. Persistent ambulatory venous hypertension promotes edema and skin injury. The discriminating principle is that venous disease reflects pressure during movement as well as pressure during quiet standing, making calf-pump function clinically important.
Apply it
An older patient with venous skin changes walks little because of ankle stiffness. Alongside vascular assessment and suitable compression, address mobility and ankle movement because an ineffective calf pump can perpetuate venous hypertension.
Common pitfall: Normal resting pulses do not demonstrate an effective venous pump. Arterial inflow and ambulatory venous pressure describe different parts of limb circulation.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
3.How do reflux and obstruction produce venous hypertension?
Reflux permits backward flow through incompetent valves, increasing distal refilling after muscular ejection. Obstruction limits forward drainage and raises upstream pressure. Either mechanism can cause edema, venous claudication, skin change, and ulceration, and both can coexist after thrombosis. Treatment planning therefore requires identifying the dominant mechanism rather than assuming that every swollen leg has superficial reflux. Deep outflow disease becomes especially relevant when symptoms exceed the superficial findings or involve the entire limb.
Apply it
A patient develops thigh and calf swelling after iliofemoral DVT, with only minor superficial reflux. Investigate deep outflow obstruction rather than attributing the entire symptom burden to the small refluxing superficial segment.
Common pitfall: A positive reflux finding does not exclude obstruction. Treating an incidental superficial abnormality may leave the principal cause of venous hypertension unresolved.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
4.What causes persistent swelling in lymphatic transport failure?
Lymphatic vessels return interstitial fluid, proteins, and other macromolecules to the circulation. Lymphedema develops when transport capacity cannot meet the tissue load because vessels are abnormal, damaged, or overwhelmed. Chronic retention promotes inflammation, fibrosis, and adipose deposition, so established swelling is not simply removable free water. Venous hypertension can increase filtration enough to overload lymphatic drainage. This explains mixed venous and lymphatic edema and the need to address both mechanisms when present.
Apply it
A patient with longstanding venous edema develops persistent foot swelling and tissue thickening despite improved venous symptoms. Recognise possible secondary lymphatic dysfunction and assess the need for a structured lymphedema treatment programme.
Common pitfall: Do not assume every edematous limb represents systemic fluid excess. Local transport failure can persist without heart failure or generalized volume overload.
International Society of Lymphology — 2023 Consensus Document
5.Why does chronic venous hypertension impair wound healing?
Sustained venous hypertension alters the microcirculation, increases fluid leakage, and promotes inflammatory tissue injury. Edema and chronic inflammation interfere with an effective healing environment, producing characteristic gaiter-region skin damage and ulceration. A dressing can manage the wound surface but cannot correct the underlying pressure disorder. Healing therefore depends on addressing venous hypertension, assessing arterial perfusion, and managing local wound factors. Persistent or atypical wounds also require reconsideration of the diagnosis rather than indefinite dressing changes.
Apply it
A shallow medial gaiter ulcer repeatedly improves and deteriorates while dressings are changed weekly. Assess perfusion and venous disease, then establish appropriate compression and a treatment plan addressing the underlying venous hypertension.
Common pitfall: Do not treat venous ulceration as an isolated skin defect. A technically suitable dressing cannot compensate for persistent, unaddressed venous hypertension.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
6.How does Virchow's triad explain venous thrombosis?
Venous thrombosis develops through interacting contributions from stasis, vessel-wall injury or activation, and hypercoagulability. Immobilisation reduces flow, surgery can injure tissue and activate coagulation, and malignancy can increase thrombotic tendency. These mechanisms often accumulate rather than act alone. Their presence informs prevention and interpretation of a thrombotic event, but risk factors do not establish the diagnosis. Suspected DVT still requires an appropriate probability-based diagnostic pathway and objective testing when indicated by that pathway.
Apply it
A patient with cancer becomes immobile after major surgery. Identify several converging thrombotic mechanisms when assessing prevention needs, while using a diagnostic algorithm if new unilateral swelling subsequently raises concern for DVT.
Common pitfall: Absence of an obvious provoking factor does not exclude thrombosis. Conversely, multiple risk factors increase suspicion but cannot independently confirm a clot.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
7.What makes factor V Leiden prothrombotic?
Factor V Leiden changes factor V so that activated protein C inactivates it less effectively. The resulting resistance prolongs procoagulant activity and increases susceptibility to venous thrombosis. Clinical expression varies substantially: many carriers never develop thrombosis, and additional inherited or acquired factors influence risk. The key distinction is resistance to an anticoagulant regulatory pathway, rather than a deficiency of factor V. A positive genetic result must therefore be interpreted within the patient's clinical history.
Apply it
A patient interprets a heterozygous factor V Leiden result as proof that another clot is inevitable. Explain the regulatory defect and variable expression, then assess the actual thrombotic history and current acquired risks.
Common pitfall: Do not confuse factor V Leiden with factor V deficiency, which is a bleeding disorder rather than this activated protein C resistance state.
8.How do anticoagulants differ from thrombolytic drugs?
Anticoagulants inhibit coagulation pathways and reduce further clot formation or extension, allowing endogenous processes to remodel thrombus over time. Thrombolytic drugs accelerate fibrin breakdown and can remove clot more rapidly, but carry greater bleeding risk. These mechanisms explain why anticoagulation is standard treatment for most DVT, whereas thrombolysis is reserved for selected situations. Persistent ultrasound abnormalities after treatment do not automatically mean anticoagulation failed, because anticoagulants are not direct clot-dissolving agents.
Apply it
A patient remains concerned that a vein is not fully recanalised shortly after anticoagulation starts. Explain that preventing extension and embolic events is the immediate aim; rapid pharmacological clot dissolution is a different intervention.
Common pitfall: Do not escalate to thrombolysis solely because residual thrombus remains visible. Clinical severity, anatomy, timing, and bleeding risk determine whether removal is appropriate.
ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
9.How does polidocanol close a treated vein?
Polidocanol is a detergent sclerosant that damages venous endothelium. The treated vessel subsequently develops occlusion and fibrotic replacement rather than closure through thermal energy. This mechanism makes accurate intravascular delivery and appropriate patient selection essential. The FDA label for Asclera concerns a specific polidocanol product and its approved uses; it should not be treated as a universal label for every foam preparation or every sclerotherapy technique. Product identity matters when interpreting indications and contraindications.
Apply it
A patient asks whether liquid polidocanol treatment burns the vein. Explain chemical endothelial injury and subsequent closure, then verify that the proposed product and target vein match the intended treatment and relevant prescribing information.
Common pitfall: Do not transfer product-specific indications or contraindications indiscriminately between liquid polidocanol, separately approved foam products, and other sclerosants used in clinical practice.
Asclera (polidocanol) Prescribing Information — Revised January 2025
10.How do ultrasound frequency and Doppler angle affect a venous examination?
Higher ultrasound frequencies improve spatial resolution but penetrate less deeply; a lower-frequency transducer may therefore be needed for deep pelvic or obese-patient imaging. Doppler frequency shift depends on the cosine of the angle between the beam and flow. Flow approaching a right angle to the beam produces little detectable shift, and inaccurate angle correction distorts velocity estimates. Low-flow venous assessment also requires suitable gain, wall-filter, and velocity-scale settings. Absent colour with unsuitable settings is not proof of occlusion.
Apply it
A deep vein appears colourless with a high-frequency probe, high wall filter, and high velocity scale. Optimise penetration and slow-flow settings, adjust the insonation angle, and assess compression where accessible before concluding that the vein is thrombosed.
Common pitfall: Do not substitute colour absence for compression assessment or compare velocity measurements obtained with inconsistent angle correction.
ABVLM Exam Content Outline Effective 2025 · IAC Standards and Guidelines for Vascular Testing Accreditation — August 3, 2026
11.How does ISSVA classification distinguish vascular tumors from malformations?
ISSVA separates vascular tumors, characterised by endothelial proliferation, from vascular malformations, which are structural abnormalities of vascular channels. Malformations are further described by their constituent vessels, including capillary, venous, lymphatic, arteriovenous, and combined lesions. Venous and lymphatic malformations are generally slow-flow lesions; arteriovenous malformations contain arterial-to-venous shunting and are fast-flow lesions. Infantile hemangioma has a characteristic proliferative and involutional course, whereas a venous malformation does not follow that natural history. Classification changes imaging and treatment selection.
Apply it
A longstanding compressible bluish lesion enlarges with dependency and shows slow venous flow without arterial shunting. Classify a suspected venous malformation rather than using hemangioma as a generic name for any vascular lesion.
Common pitfall: Do not use tumor and malformation interchangeably or select treatment without establishing whether a lesion contains a fast-flow shunt.
ABVLM Exam Content Outline Effective 2025 · ISSVAUpdatedflowdiagram_03152025_copyright_3.21.25.pdf
12.Which nerves are vulnerable near saphenous treatment sites?
The saphenous nerve lies close to the great saphenous vein in the distal leg, and the sural nerve can lie close to the small saphenous vein, particularly distally. These relationships make distal thermal treatment and surgical manipulation relevant causes of sensory injury. Risk assessment should consider the planned treatment length and local anatomy rather than the vein name alone. A sensory deficit after treatment should be mapped and assessed instead of being dismissed as routine bruising.
Apply it
A patient needs treatment of small saphenous reflux extending distally. Review the vein's relationship to nearby nerves and consider whether limiting thermal extent or choosing another approach would reduce sensory injury risk for this anatomy.
Common pitfall: Do not assume the same nerve risk throughout a saphenous trunk. Distal anatomy may create a different risk from the proximal treatment segment.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
13.How should infection control change between diagnostic scanning and percutaneous treatment?
Hand hygiene, appropriate gloves, environmental cleaning, and equipment reprocessing interrupt transmission between patients. A transducer contacting intact skin requires cleaning and appropriate disinfection between patients. Percutaneous venous access additionally requires skin antisepsis, aseptic handling, and a sterile procedural field; ultrasound guidance within that field requires a sterile probe cover and sterile gel. A cover does not replace probe cleaning or the level of disinfection required by its actual use and contamination. Reusable equipment must be processed according to its contact risk and manufacturer instructions.
Apply it
After diagnostic mapping, a clinician proceeds to ultrasound-guided venous access. Prepare the access site and sterile equipment, cover the appropriately processed probe, and use sterile gel rather than carrying the diagnostic setup directly into the puncture procedure.
Common pitfall: Do not treat a new probe cover as proof that the underlying transducer was adequately reprocessed, or allow a nonsterile gel container to contaminate the procedural field.
ABVLM Exam Content Outline Effective 2025 · IAC Standards and Guidelines for Vascular Testing Accreditation — August 3, 2026
Diagnostic evaluation32%
14.Which symptom pattern supports chronic venous disease?
Venous symptoms commonly include aching, heaviness, swelling, itching, and discomfort associated with prolonged dependency. Improvement with elevation or walking can support a venous contribution, but these symptoms are not specific enough to establish causation. History should connect symptoms with posture, activity, prior thrombosis, pregnancy, procedures, and skin changes. Duplex findings must then be interpreted against the clinical pattern. An anatomical reflux abnormality is more persuasive when it plausibly explains the patient's location and type of symptoms.
Apply it
A patient has small varices but pain mainly triggered by spinal movement and radiating down the leg. Evaluate a neurological cause while assessing venous disease; the visible veins alone do not establish the pain's origin.
Common pitfall: Do not attribute every painful leg with varices to venous reflux. Symptom distribution and provoking factors may identify a different dominant disorder.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
15.How should the distribution of edema guide investigation?
Edema distribution helps frame a differential diagnosis without establishing one by itself. Acute unilateral swelling raises concern for local venous thrombosis or another focal process; chronic whole-limb swelling can suggest proximal outflow disease. Bilateral edema requires consideration of systemic disease, medications, venous hypertension, and lymphatic dysfunction. Foot involvement, tissue texture, skin change, time course, and response to elevation add discriminatory value. A focused assessment should identify the mechanism before compression or an invasive venous procedure is selected.
Apply it
A patient has new bilateral ankle swelling after a medication change, without focal pain or venous skin changes. Review systemic and medication causes before interpreting a small incidental reflux finding as the explanation for both limbs.
Common pitfall: Do not use unilateral versus bilateral swelling as an absolute rule. Venous and lymphatic disorders can be bilateral, and systemic disease can produce asymmetry.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs · International Society of Lymphology — 2023 Consensus Document
16.How is the ankle-brachial index calculated?
For each leg, divide the higher systolic pressure from that ankle's dorsalis pedis or posterior tibial artery by the higher brachial systolic pressure. Calculate each leg separately rather than averaging ankle pressures across limbs. An ABI of 0.90 or less is abnormal, 0.91–0.99 is borderline, 1.00–1.40 is normal, and above 1.40 is noncompressible. Interpretation must account for symptoms and technical limitations, particularly when assessing arterial safety before a compression prescription.
Apply it
The higher brachial pressure is 150 mmHg; right dorsalis pedis and posterior tibial pressures are 105 and 120 mmHg. The right ABI is 120 divided by 150, or 0.80, supporting arterial disease.
Common pitfall: Do not use the lower ankle pressure or average both arms. The standard calculation uses the higher ankle artery and higher brachial pressure.
2024 ACC/AHA Multisociety Guideline for Lower Extremity Peripheral Artery Disease
17.When does a high ABI require toe-pressure testing?
An ABI above 1.40 suggests noncompressible ankle arteries rather than exceptionally good perfusion. Medial arterial calcification, often associated with diabetes or chronic kidney disease, can prevent accurate cuff compression. Toe pressure and the toe-brachial index, together with waveforms, provide an alternative assessment because digital arteries are usually less affected. The decision is especially important before compression or when evaluating a wound: a falsely elevated ankle pressure must not conceal clinically important arterial insufficiency.
Apply it
A patient with diabetes has a foot wound and ABI of 1.55. Obtain toe pressure or toe-brachial testing with waveforms rather than accepting the ankle result as reassurance that perfusion is adequate for healing.
Common pitfall: Do not interpret every ABI above 1.00 as normal. Values above the noncompressibility threshold require a different assessment of distal perfusion.
2024 ACC/AHA Multisociety Guideline for Lower Extremity Peripheral Artery Disease
18.What ultrasound finding most directly supports lower-limb DVT?
Failure of a vein to compress completely under appropriate probe pressure is a central ultrasound sign of DVT in accessible venous segments. Colour and spectral Doppler add information but do not replace technically adequate compression assessment. Echogenicity alone cannot reliably establish thrombus age, and residual post-thrombotic change can complicate interpretation. The report should identify the segments examined, abnormalities, and limitations. A limited study must be interpreted within the diagnostic pathway rather than treated as a complete exclusion.
Apply it
A symptomatic popliteal vein contains some colour flow but does not compress fully. Treat noncompressibility as a significant thrombotic finding; preserved flow can occur around a nonocclusive clot and does not independently exclude DVT.
Common pitfall: Do not exclude DVT because colour is visible in the lumen. Nonocclusive thrombus may permit flow while preventing complete venous compression.
IAC Standards and Guidelines for Vascular Testing Accreditation — August 3, 2026 · ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
19.Which reflux durations distinguish superficial and major deep veins?
The SVS/AVF/AVLS guidance defines reflux as reversed flow exceeding 500 milliseconds in superficial truncal veins and exceeding one second in the common femoral, femoral, and popliteal veins. These thresholds are segment-specific, so one universal cutoff should not be applied throughout the limb. Reflux should be elicited and measured with an appropriate maneuver and position. A threshold establishes an abnormal flow finding, while symptom correlation and anatomical extent determine its clinical significance and treatment implications.
Apply it
A dependent great saphenous vein shows 0.8 seconds of reverse flow after release of distal compression. This meets the superficial reflux definition; the same duration in a popliteal vein would not meet its threshold.
Common pitfall: Do not apply the one-second deep-vein threshold to superficial trunks, or assume that any measurable reverse flow establishes clinically important reflux.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
20.How should position and provocation support a reflux study?
A reflux examination should evaluate veins under conditions that permit venous filling, preferably with the patient standing when feasible. Reverse Trendelenburg or another dependent arrangement may be needed when standing is unsafe. Distal compression and release or Valsalva are selected according to the segment examined. Documenting position, maneuvers, duration, diameter, and anatomical distribution makes findings interpretable. A poorly filled supine vein or an inadequate provocative maneuver can produce misleading reassurance despite a clinically suggestive history.
Apply it
A patient with dependency-related varices has a negative reflux study performed flat without documented provocation. Review technical adequacy and consider a properly dependent examination before concluding that valvular incompetence is absent in the symptomatic limb.
Common pitfall: Do not treat an undocumented negative study as definitive. Position and the quality of provocation materially affect whether reflux can be demonstrated.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II · IAC Standards and Guidelines for Vascular Testing Accreditation — August 3, 2026
21.What can an abnormal common femoral waveform suggest?
Lower-extremity venous waveforms normally show variation with respiration. Markedly reduced phasicity or a continuous pattern, particularly when asymmetric and accompanied by whole-limb swelling or collateral veins, can suggest more proximal outflow obstruction. This is an indirect clue, not a precise anatomical diagnosis. Pelvic or abdominal disease may lie outside a routine leg compression examination. Additional imaging should be selected when the clinical pattern and indirect findings justify investigating iliac or caval drainage.
Apply it
A patient has left whole-leg edema, abdominal wall collaterals, and a continuous left common femoral waveform despite compressible femoropopliteal veins. Investigate proximal outflow rather than declaring the venous evaluation normal on compression findings alone.
Common pitfall: Do not diagnose a specific iliac lesion from waveform shape alone. Technical factors and physiological variation require clinical correlation and appropriate confirmatory imaging.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs · IAC Standards and Guidelines for Vascular Testing Accreditation — August 3, 2026
22.How do Wells and Caprini assessments serve different decisions?
A Wells assessment estimates the pretest probability of an existing DVT in a symptomatic patient and helps select a diagnostic pathway. A Caprini assessment estimates perioperative VTE risk and can inform prophylaxis planning in an appropriate surgical population. These purposes are different: a prevention score cannot replace diagnostic probability assessment, and a diagnostic score does not itself prescribe perioperative prevention. Both require accurate clinical inputs and use within the population and protocol for which they are intended.
Apply it
A postoperative patient develops new unilateral calf swelling. Use a suspected-DVT diagnostic pathway rather than relying on the preoperative Caprini result, which addressed prevention risk before symptoms arose rather than whether thrombosis is now present.
Common pitfall: Do not substitute one risk score for another because both concern thrombosis. Prediction of future risk and diagnosis of current disease require different reasoning.
ABVLM Exam Content Outline Effective 2025 · ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
23.When can a negative D-dimer exclude DVT?
A negative highly sensitive D-dimer can exclude DVT when used within a validated low-pretest-probability pathway. Its value depends on the starting probability, assay sensitivity, and correct application of the algorithm. The same negative result should not be used as a universal rule-out in a high-probability presentation. A positive result does not diagnose thrombosis; it directs further assessment, usually ultrasound. Probability assessment therefore precedes interpretation rather than being inferred from the laboratory result afterward.
Apply it
An ambulatory patient has low clinical probability of first lower-limb DVT and a negative highly sensitive D-dimer. In the appropriate validated pathway, further DVT imaging is unnecessary unless another clinical concern changes the assessment.
Common pitfall: Do not interpret D-dimer in isolation. A rule-out strategy valid at low probability may be inadequate when the clinical probability is high.
ASH — Diagnosis of Venous Thromboembolism: Guideline Teaching Slides
24.When is serial ultrasound needed after an initial negative study?
ASH distinguishes intermediate- from high-pretest-probability pathways. At intermediate probability, a technically adequate negative whole-leg ultrasound can complete assessment; a negative proximal examination generally requires serial proximal ultrasound if no alternative diagnosis explains the presentation. In the high-probability pathway, an initially negative proximal or whole-leg examination should be followed by serial ultrasound when no alternative diagnosis is identified. Serial ultrasound generally means one additional examination about one week later. Greater anatomical coverage therefore does not automatically complete a high-probability workup.
Apply it
A patient with high DVT probability has persistent unexplained swelling after a negative initial ultrasound. Arrange serial imaging through the high-probability pathway even if the initial examination included calf veins.
Common pitfall: Do not transfer the intermediate-probability stopping rule after negative whole-leg imaging to ASH's high-probability pathway.
ASH — Diagnosis of Venous Thromboembolism: Guideline Teaching Slides
25.How do dynamic venous tests distinguish reflux from poor calf-pump emptying?
Air plethysmography measures changes in limb volume during filling and exercise. An increased venous filling index supports excessive reflux; a reduced ejection fraction indicates impaired emptying during calf contraction. An elevated residual volume fraction reflects incomplete overall emptying and can result from reflux, pump dysfunction, or both. Photoplethysmography assesses refilling after exercise: rapid refilling supports reflux but does not precisely localise it. Ambulatory venous pressure should fall with effective exercise; persistent elevation indicates inadequate pressure relief. These functional tests complement anatomical duplex mapping.
Apply it
A patient with limited ankle movement has a low plethysmographic ejection fraction despite little duplex-demonstrated reflux. Consider calf-pump dysfunction and mobility treatment rather than interpreting every abnormal functional result as a target for vein ablation.
Common pitfall: Do not infer the exact refluxing vein from a global refilling measurement or treat a high residual volume fraction as a mechanism-specific diagnosis.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs · ABVLM Exam Content Outline Effective 2025
26.How does CEAP distinguish healed from active venous ulceration?
CEAP describes chronic venous disease through clinical, etiological, anatomical, and pathophysiological components. Within the clinical component, C5 denotes healed venous ulceration and C6 denotes active venous ulceration. C3 describes edema, while C4 encompasses venous skin and subcutaneous changes. Healing therefore changes the ulcer-related clinical category without erasing the history of advanced disease. CEAP communicates disease phenotype, but it is not a substitute for a longitudinal severity score or an investigation of the underlying mechanism.
Apply it
A previously open medial gaiter ulcer has completely epithelialised, leaving venous skin changes. Record healed ulceration as C5 rather than retaining C6 or downgrading the limb to a category that omits its ulcer history.
Common pitfall: Do not classify a fully healed ulcer as active because discoloration remains. Conversely, a smaller but still open venous ulcer remains active ulceration.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
27.Why use VCSS alongside CEAP?
The revised Venous Clinical Severity Score grades clinically important features such as pain, varicose veins, edema, skin changes, ulcer characteristics, and compression use. It is designed to capture severity and change more responsively than a descriptive CEAP category alone. A patient can improve substantially while remaining in the same CEAP class, particularly when a healed-ulcer history persists. Serial scoring should use consistent definitions and be interpreted alongside symptoms, examination, and patient-reported quality of life rather than as an isolated number.
Apply it
After treatment, a patient with a healed ulcer remains C5 but reports less pain and has less edema. Use consistent VCSS assessment and patient-reported outcomes to document improvement that the unchanged CEAP class cannot fully show.
Common pitfall: Do not interpret an unchanged CEAP category as proof of treatment failure. Classification and severity measurement have related but different clinical purposes.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
28.How is the Villalta scale scored and interpreted?
Score five symptoms—pain, cramps, heaviness, paresthesia, and pruritus—and six signs—pretibial edema, skin induration, hyperpigmentation, redness, venous ectasia, and pain on calf compression. Each receives 0 for absent, 1 for mild, 2 for moderate, or 3 for severe. A total below 5 indicates no post-thrombotic syndrome, 5–9 mild, 10–14 moderate, and at least 15 or venous ulceration severe PTS. Assess after the acute phase, generally at 3–6 months or later, and consider pre-existing venous disease and competing diagnoses.
Apply it
Months after DVT, symptom scores of 2, 1, 2, 0, and 1 total 6. Sign scores of 2, 1, 1, 0, 1, and 0 total 5. The combined score is 11, indicating moderate PTS if the findings are attributable to post-thrombotic disease.
Common pitfall: Do not diagnose chronic PTS from acute DVT symptoms or let a Villalta score explain sudden deterioration without assessing recurrent thrombosis or another acute cause.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
29.How do ISL stages distinguish fluid reversibility from tissue change?
ISL stage 0 describes impaired lymph transport without overt swelling. Stage I usually includes swelling that subsides with elevation and may pit. Stage II does not resolve with elevation alone; pitting may occur early, while fibrosis and fat accumulation can reduce pitting later. Stage III includes marked tissue and skin changes. The key progression is from more reversible fluid accumulation toward structural tissue remodeling. Absence of pitting therefore does not exclude advanced lymphedema or imply that the swelling is insignificant.
Apply it
A patient has chronic limb enlargement that persists overnight and has become firm with little pitting. Consider established stage II tissue remodeling rather than excluding lymphedema because finger pressure no longer leaves a substantial indentation.
Common pitfall: Do not equate nonpitting swelling with absence of lymphatic disease. Fibrosis and adipose deposition can make longstanding lymphedema less compressible on examination.
International Society of Lymphology — 2023 Consensus Document
30.When does lymphatic imaging add diagnostic value?
Lymphedema is often diagnosed from history and examination, but imaging can clarify uncertain cases or support procedural planning. Lymphoscintigraphy assesses transport using a tracer, while indocyanine-green lymphography depicts superficial lymphatic pathways and dermal backflow. Other modalities can provide complementary anatomical information. The choice should match the clinical question and local expertise. Imaging is especially useful when the phenotype is atypical, several mechanisms may coexist, or a specialist needs to map channels before a lymphatic intervention.
Apply it
A patient has persistent unilateral swelling with an inconclusive clinical assessment after venous causes have been evaluated. Select lymphatic imaging to clarify transport dysfunction, rather than repeating unrelated venous tests without a new diagnostic question.
Common pitfall: Do not assume every lymphatic imaging method measures the same feature. Superficial channel mapping and whole-limb transport assessment provide different, complementary information.
International Society of Lymphology — 2023 Consensus Document
31.How do IVUS and venography complement each other?
Venography depicts contrast flow and collateral pathways, but its two-dimensional projections may underestimate the shape or extent of an iliac lesion. Intravascular ultrasound provides cross-sectional information about lumen size, wall features, and lesion morphology and can guide sizing and landing zones when intervention is justified. The methods are complementary rather than interchangeable. Neither imaging abnormality alone establishes that a nonthrombotic iliac lesion causes symptoms; clinical selection must precede the decision to implant a permanent venous stent.
Apply it
A carefully selected symptomatic patient has suspected iliac obstruction with an inconclusive venogram. Use IVUS as complementary intraprocedural assessment rather than treating one apparently mild projection as a definitive measurement of the entire venous lumen.
Common pitfall: Do not let a striking IVUS image replace symptom attribution. Anatomical compression is common enough that an imaging finding alone does not justify stenting.
32.When should CT or MR venography extend a leg ultrasound assessment?
Cross-sectional venous imaging can evaluate pelvic and abdominal segments that are poorly visualised on routine leg ultrasound. It may identify the level of obstruction, collateral pathways, extrinsic compression, or another pelvic process. CT and MR have different contrast, radiation, device, and technical considerations, so selection depends on the patient and diagnostic question. A static narrowing can also reflect physiological or positional variation. Cross-sectional anatomy should support a clinically coherent diagnosis rather than automatically trigger an intervention.
Apply it
Whole-leg swelling and pelvic collaterals persist despite a negative femoropopliteal DVT study. Consider pelvic or abdominal venous imaging to assess proximal drainage and possible extrinsic disease beyond the routine ultrasound field of view.
Common pitfall: Do not regard a normal calf-to-groin study as complete assessment of pelvic outflow. Conversely, an incidental cross-sectional narrowing may have no clinical consequence.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs · NIVL-Management-Consensus.pdf
Knowledge and skills integral to the practice of venous and lymphatic medicine28%
33.When does arterial disease restrict sustained compression?
Compression safety depends on arterial perfusion, not merely the presence of venous edema. The international consensus identifies severe arterial disease, including ankle systolic pressure below 60 mmHg or toe pressure below 30 mmHg, as a contraindication to sustained medical compression stockings. These limits should not be converted into a blanket prohibition on every device or specialist-selected approach. Borderline perfusion, neuropathy, and tissue vulnerability require individual assessment, careful selection, and monitoring rather than routine high-pressure treatment.
Apply it
A patient with a venous-appearing ulcer has ankle pressure of 50 mmHg. Withhold routine sustained stocking compression and obtain arterial assessment; do not assume that the ulcer's appearance makes standard venous compression safe.
Common pitfall: Do not generalise a contraindication to sustained stockings into an identical rule for every compression modality. Specialist-selected low-resting-pressure approaches require separate clinical judgment.
Risks and Contraindications of Medical Compression Treatment — International Consensus Statement
34.How do short-stretch bandages differ from elastic stockings?
Short-stretch systems resist expansion and can generate substantial working pressure when muscles contract against them. Their resting behavior differs from more elastic systems, and the achieved pressure depends on application, limb shape, padding, and movement. They can be useful during decongestion when limb volume changes quickly. Stockings may become more practical for maintenance after volume stabilises. Neither category is inherently safe in every patient; perfusion, sensation, fitting, and the person's ability to apply and tolerate treatment remain essential.
Apply it
A patient begins intensive limb-volume reduction and the circumference changes over several days. Use an appropriately supervised bandaging or adjustable system during decongestion, then reassess maintenance garment measurements after the limb volume has stabilised.
Common pitfall: Do not assume a bandage delivers a fixed pressure because its material is named. Technique, tension, overlap, padding, and limb geometry alter the result.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs · Risks and Contraindications of Medical Compression Treatment — International Consensus Statement
35.How should local wound care support venous ulcer treatment?
Local care should manage exudate, protect surrounding skin, and support an appropriate wound environment while the venous pressure disorder is treated. Dressing selection depends on wound characteristics and patient tolerance rather than an assumption that one material heals every venous ulcer. Debridement decisions must consider perfusion and tissue condition. Antibiotics address clinical infection, not simple bacterial colonisation. The main decision is to integrate local care with suitable compression and venous assessment instead of expecting topical treatment to correct hemodynamics.
Apply it
An exudative gaiter ulcer has macerated surrounding skin but no spreading erythema or systemic illness. Improve exudate control and skin protection, reassess compression and perfusion, and avoid prescribing antibiotics solely because the wound is colonised.
Common pitfall: Do not confuse a positive wound culture with clinical infection. Surface organisms alone do not establish a need for systemic antibiotic treatment.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs · venous%20leg%20ulcer%20assessment%20section-2025.pdf
36.How should thermal and nonthermal ablation be selected?
Laser and radiofrequency ablation heat the vein wall, causing injury, contraction, and eventual fibrotic closure. Perivenous tumescence provides local anesthesia, compresses the vein around the device, and creates a heat-protective fluid layer separating skin and nerves; ultrasound must confirm its distribution along the treated segment. Foam sclerotherapy causes chemical endothelial injury but may have lower durable truncal occlusion and require repeat treatment. Cyanoacrylate polymerises within the vein, adhering its walls without thermal tumescence, but leaves adhesive material and can cause inflammatory or hypersensitivity reactions. Mechanochemical ablation combines mechanical endothelial injury with sclerosant delivery; closure durability, particularly in larger trunks, can limit selection. Tortuosity affects catheter access, while superficial location and distal nerve proximity increase thermal-injury concerns.
Apply it
A refluxing distal segment closely follows a sensory nerve. Compare a nonthermal approach or limited thermal extent with ultrasound-confirmed protective tumescence, considering vein diameter, access, product allergy, durability, and the patient's preferences.
Common pitfall: Do not equate nonthermal treatment with absence of risk, or assume that injecting a recorded fluid volume proves adequate circumferential thermal protection.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
37.When does tributary treatment differ from truncal ablation?
Truncal ablation targets an incompetent saphenous pathway, while phlebectomy or sclerotherapy can address symptomatic tributary varices. The procedures solve related but distinct anatomical problems. Duplex mapping determines whether tributaries arise from truncal reflux, another source, or isolated local disease. Treatment may be combined or staged according to the clinical situation and patient preference. Persistent tributaries after successful truncal closure do not necessarily mean the trunk has recanalised, so reassessment should identify the remaining source before additional treatment.
Apply it
After confirmed great saphenous closure, a patient still has a painful bulging calf tributary. Reassess its connections and consider tributary-directed treatment rather than repeating truncal ablation without evidence that the treated trunk has reopened.
Common pitfall: Do not equate every residual visible varix with truncal treatment failure. Tributaries can remain symptomatic despite successful closure of the original refluxing trunk.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
38.Why use ultrasound guidance for deeper sclerotherapy targets?
Ultrasound guidance helps identify the target vein, adjacent arteries, needle position, and distribution of the injected material when a target is not reliably treated by direct visualisation. This supports accurate delivery but does not eliminate risks such as extravasation, thrombosis, or inadvertent arterial injection. The operator must understand both local anatomy and the behavior of the chosen sclerosant. New severe pain, blanching, or unexpected resistance during injection should prompt immediate reassessment rather than continued injection through uncertainty.
Apply it
A recurrent varix lies beneath scarred tissue and cannot be confidently followed on the skin. Use ultrasound to confirm anatomy and intravascular access before treatment, and stop if unexpected pain or tissue changes occur during injection.
Common pitfall: Do not assume a needle is safely intravascular because blood was aspirated earlier. Position can change, and adjacent arterial anatomy requires continuing attention.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
39.Which contraindications are explicit for Asclera?
The Asclera prescribing information lists known allergy to polidocanol and acute thromboembolic disease as contraindications. These are product-specific prescribing boundaries that should be checked before an elective procedure. The label also warns about serious allergic reactions, thrombosis, and tissue injury, making readiness to recognise and manage complications essential. A history of uneventful treatment does not replace an updated assessment. Distinguish contraindications from warnings and from eligibility for other products or techniques rather than merging all sclerotherapy into one rule.
Apply it
A patient scheduled for elective Asclera treatment reports a newly diagnosed acute DVT. Defer that product's treatment because acute thromboembolic disease is an explicit contraindication, rather than proceeding because the planned target veins are small.
Common pitfall: Do not assume small target veins remove systemic contraindications. Product-specific screening remains necessary even when the planned intervention appears limited or cosmetic.
Asclera (polidocanol) Prescribing Information — Revised January 2025
40.How should anaphylaxis and local anesthetic systemic toxicity be distinguished and managed initially?
Acute bronchospasm, laryngeal swelling, or hypotension after a likely allergen suggests anaphylaxis, even without urticaria. Stop exposure, summon emergency assistance, give intramuscular epinephrine promptly, and support airway, oxygenation, and circulation. LAST may begin with circumoral numbness, metallic taste, tinnitus, or agitation and progress to seizure, arrhythmia, hypotension, or arrest. Stop local anesthetic administration, call for help and the LAST rescue kit, and ensure oxygenation and ventilation. Treat seizures preferentially with a benzodiazepine. Seizure or cardiovascular toxicity consistent with LAST warrants early consideration of 20% intravenous lipid emulsion using the ASRA checklist; do not wait for cardiac arrest. LAST resuscitation differs from standard ACLS: use smaller epinephrine doses, initially below 1 microgram/kg, and avoid vasopressin, beta-blockers, calcium-channel blockers, and additional local anesthetics, including lidocaine as an antiarrhythmic.
Apply it
Wheeze, urticaria, and hypotension after sclerosant exposure require prompt anaphylaxis treatment. Tinnitus and circumoral numbness progressing to seizure during anesthetic infiltration require stopping injection, airway and oxygenation support, benzodiazepine treatment, and early lipid-rescue consideration.
Common pitfall: Do not delay intramuscular epinephrine for anaphylaxis while giving antihistamines. During suspected LAST, do not continue anesthetic injection or apply unmodified ACLS drug treatment.
local-anesthetic-systemic-toxicity-rgb.pdf · Local Anesthetic Systemic Toxicity (LAST): A Problem-Based Learning Discussion · WAO-Anaphylaxis-2020.pdf
41.How should initial anticoagulant selection account for patient factors and initiation requirements?
For many adults with DVT or PE, ASH favors a direct oral anticoagulant over a vitamin K antagonist, subject to patient suitability. Renal or hepatic dysfunction, interacting drugs, antiphospholipid syndrome, absorption, cost, and adherence can alter selection. Dabigatran and edoxaban require preceding therapeutic parenteral anticoagulation, generally for 5–10 days. Apixaban and rivaroxaban have oral initiation regimens with an initial higher-dose phase and do not require that parenteral lead-in. Check the selected agent's prescribing information for the complete regimen and organ-function restrictions.
Apply it
A patient with new proximal DVT wants an entirely oral initial regimen. Distinguish apixaban or rivaroxaban initiation from dabigatran or edoxaban, then check interactions, organ function, and suitability before selecting treatment.
Common pitfall: Do not start dabigatran or edoxaban as though they use the same acute oral initiation schedule as apixaban or rivaroxaban.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis · ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
42.How do primary treatment and secondary VTE prevention differ?
Primary treatment addresses the presenting DVT or PE, commonly over three to six months in the ASH framework. Secondary prevention concerns whether anticoagulation should continue afterward to reduce recurrence. A transient provoking factor, persistent risk factor, unprovoked event, prior history, and bleeding risk influence that later decision. Completing primary treatment does not automatically mean either stopping or continuing indefinitely. The distinction prevents a short initial prescription from becoming an unreviewed long-term plan without explicit reassessment of benefit and harm.
Apply it
At follow-up after treatment of a first DVT associated with a resolved temporary trigger, reassess recurrence and bleeding risks before stopping. Contrast that decision with an unprovoked event or persistent risk factor rather than applying one duration universally.
Common pitfall: Do not treat primary-treatment duration as an automatic answer to secondary prevention. The later decision requires a separate assessment of recurrence risk and bleeding.
ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
43.When may thrombus-removal treatment be justified for DVT?
Anticoagulation alone is appropriate for most proximal DVT. Thrombolysis or another thrombus-removal strategy may be considered for limb-threatening thrombosis or selected patients with symptomatic iliofemoral disease, favorable functional status, and acceptable bleeding risk. Anatomy, symptom duration, severity, and patient priorities matter. The potential to improve early symptoms or reduce selected later consequences must be weighed against procedural and bleeding harms. Routine escalation for every proximal clot is not supported simply because rapid removal is technically possible.
Apply it
A mobile patient with severe recent iliofemoral symptoms and low bleeding risk asks about intervention. Arrange specialist assessment of benefits and harms, while distinguishing this situation from a mildly symptomatic femoropopliteal DVT usually treated with anticoagulation alone.
Common pitfall: Do not select thrombolysis solely from the word proximal. Iliac involvement, symptom burden, timing, functional status, and bleeding risk materially change the decision.
ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
44.When is an inferior vena cava filter appropriate?
A vena cava filter can reduce embolisation from lower-body venous thrombus but does not treat the existing clot or prevent all future thrombosis. For patients who can receive therapeutic anticoagulation, ASH generally favors anticoagulation without adding a filter. An acute VTE patient with a contraindication to anticoagulation may require a retrievable filter, with reassessment and removal once anticoagulation becomes possible. The decision should include a follow-up plan because an initially temporary device can otherwise become an unintended permanent exposure.
Apply it
A patient with acute proximal DVT has active major bleeding that prevents anticoagulation. Consider a retrievable filter within specialist care and establish reassessment for anticoagulation and retrieval when the bleeding contraindication has resolved.
Common pitfall: Do not add a filter routinely to effective anticoagulation for reassurance. The device introduces its own risks and does not replace appropriate anticoagulant treatment.
ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
45.What are the two phases of complete decongestive therapy?
Complete decongestive therapy combines skin care, exercise, compression, and selected manual lymphatic techniques within a structured programme. An initial reduction phase commonly uses multilayer bandaging and therapist-directed care. A maintenance phase then sustains volume control with appropriate garments, self-management, activity, and continued skin care. Manual treatment alone is not equivalent to the full programme. Routine long-term diuretics do not restore lymph transport and are discouraged for isolated lymphedema, although a separate condition such as heart failure may justify them.
Apply it
After intensive treatment reduces a patient's limb volume, arrange a properly fitted maintenance garment and teach daily care. Discharge without a maintenance plan risks losing the improvement achieved during the initial supervised reduction phase.
Common pitfall: Do not describe complete decongestive therapy as massage alone or substitute chronic diuresis for treatment of isolated lymphatic transport failure.
International Society of Lymphology — 2023 Consensus Document
46.How does flow classification guide vascular-malformation treatment?
Use ISSVA terminology to identify the vascular components and flow category, then define lesion extent and drainage. Symptomatic slow-flow venous malformations may undergo image-guided sclerotherapy, selected excision, or combined treatment. For lymphatic malformations, sclerotherapy response depends on cystic morphology: accessible macrocysts generally respond better than diffuse microcystic components. Anatomical site also changes risk; inflammatory swelling after treatment near the airway can cause obstruction. The Japanese vascular-anomaly guideline discusses these morphology and site distinctions in its lymphatic-malformation sections, CQs 24–25 and CQ 29. Fast-flow arteriovenous malformation treatment targets the shunting nidus with embolization and selected surgery. Proximal feeding-artery occlusion alone can recruit collaterals and compromise subsequent access. Pulsed-dye laser can treat superficial capillary malformations. Across these categories, classification informs treatment selection but does not replace anatomical assessment.
Apply it
A symptomatic lymphatic malformation contains large, accessible cysts on imaging. These provide targets for drainage and sclerosant delivery. A predominantly microcystic lesion offers less accessible cystic space and a less predictable response. If either lesion involves the tongue or neck near the airway, anticipated treatment-related swelling must inform airway protection and postprocedure monitoring. Separately, arterialized venous flow in a presumed venous malformation should trigger reassessment for arteriovenous shunting before injection.
Common pitfall: Surface color alone cannot establish flow classification or select treatment. Assess deep-vein communication before venous-malformation sclerotherapy because unintended sclerosant passage can injure the deep venous system and cause thrombosis. Do not assume that all lymphatic malformations respond equally or that volume reduction carries the same risk at every anatomical site.
ISSVAUpdatedflowdiagram_03152025_copyright_3.21.25.pdf · ABVLM Exam Content Outline Effective 2025 · Client Challenge
47.How should VTE prophylaxis be selected around superficial venous intervention?
Assess thrombosis risk and bleeding risk before intervention rather than prescribing the same prophylaxis to every patient. Relevant thrombotic considerations include previous VTE, thrombophilia, active cancer, reduced mobility, obesity, hormone exposure, and procedural extent. The SVS/AVF/AVLS guideline suggests pharmacological thromboprophylaxis for high-risk patients undergoing endovenous ablation and recommends routine risk stratification. Agent and duration require individual selection because one universal regimen is not established. Early mobilisation supports prevention but does not replace indicated pharmacological prophylaxis.
Apply it
A patient with previous VTE, restricted mobility, and planned combined venous procedures needs explicit assessment of prophylaxis benefit against bleeding risk before the intervention.
Common pitfall: Do not use a low-risk outpatient label to override important patient-specific risks or treat prophylactic anticoagulation as equivalent to therapeutic treatment of confirmed DVT.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
48.How do SVT length and junctional distance change treatment?
Obtain whole-leg duplex to measure spontaneous SVT and exclude associated DVT. ESVS generally recommends no anticoagulation for isolated SVT shorter than 5 cm without high-risk features, and a 45-day regimen for sufficiently extensive SVT away from the deep junction. Its recommendation 48 includes thrombus at or within 3 cm in the therapeutic-anticoagulation branch, although the accompanying flowchart uses a different boundary. For main-saphenous SVT at the saphenofemoral junction, the 2023 SVS/AVF/AVLS statement 12.1.2 explicitly recommends full anticoagulation when the thrombus is at or within 3 cm, for at least six weeks. Thus exactly 3 cm must not automatically enter the lower-intensity branch. Above-knee saphenous SVT more than 3 cm from the SFJ and at least 5 cm long fits the usual 45-day fondaparinux regimen. High-risk features can justify longer treatment.
Apply it
An 8-cm great saphenous SVT ending 5 cm from the SFJ fits the usual 45-day branch. If its proximal end is exactly 3 cm from the SFJ, apply the SVS/AVF/AVLS junction-adjacent full-anticoagulation recommendation.
Common pitfall: Do not combine inequalities from different guideline diagrams into a universal rule. Identify the guideline, anatomical junction, thrombus length, associated DVT, and risk features; ablation-related extension uses a separate framework.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis · 2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
49.How should active bleeding from a varicose vein be controlled initially?
Initial control of external varicose bleeding uses limb elevation and firm direct pressure over the bleeding site, with urgent assistance according to severity and the patient's condition. Once controlled, the patient needs assessment of the underlying venous source and a plan to prevent recurrence. A fragile skin surface over a pressurised superficial vein can bleed significantly, especially when the limb remains dependent. Temporary haemostasis therefore addresses the emergency but does not complete management of the causal venous disease.
Apply it
A patient develops brisk bleeding from an ankle varix while standing. Elevate the leg and apply direct pressure immediately, then arrange urgent evaluation and subsequent venous assessment even if the bleeding stops with first aid.
Common pitfall: Do not let successful pressure control end follow-up. Recurrent bleeding remains possible until the responsible venous disease and vulnerable local skin are addressed.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
Clinical management19%
50.Which patients and timing define the EVRA evidence for early ablation?
EVRA enrolled patients with active venous ulcers of approximately six weeks to six months' duration, ABPI at least 0.8, ability to tolerate compression, and superficial reflux suitable for endovenous treatment. Early ablation meant treatment within two weeks of randomisation, alongside compression. This strategy accelerated healing compared with deferred ablation. These are trial eligibility and timing criteria, not universal restrictions on treating ulcers outside that population. Patients with different perfusion, ulcer duration, or anatomy require an assessment of how well the evidence applies.
Apply it
A patient with a three-month venous ulcer, ABPI 0.95, compression tolerance, and suitable superficial reflux resembles the studied population. Discuss prompt ablation alongside compression rather than automatically waiting for wound closure.
Common pitfall: Do not equate early treatment with an undefined future appointment or describe ablation as a replacement for the compression used in the trial.
Early Versus Deferred Endovenous Ablation in Venous Ulceration — EVRA RCT
51.How should recurrent varicose veins be reassessed?
Recurrent varices can arise from recanalisation, residual reflux, new disease in another segment, neovascular connections, or a pelvic or perforator source. The original procedure does not determine the current mechanism. History, examination, and duplex should map the present source and assess whether symptoms correspond to it. Treatment should then target the demonstrated pathway. Repeating the previous intervention without remapping risks treating a closed or irrelevant segment while leaving the active source of recurrent venous hypertension untreated.
Apply it
Years after great saphenous treatment, a patient develops new posterior thigh varices. Map the current reflux pathways, including nonsaphenous sources when indicated, rather than assuming the original great saphenous trunk has necessarily reopened.
Common pitfall: Do not equate recurrence with operator failure or recanalisation alone. Venous disease can progress through anatomical pathways that were not responsible for the original presentation.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
52.How does post-thrombotic syndrome develop after DVT?
Residual obstruction and valve damage after DVT can produce chronic venous hypertension, leading to heaviness, swelling, skin change, and occasionally ulceration. Post-thrombotic syndrome is a clinical consequence of the prior event rather than simply a persistent clot image. Management addresses symptoms, mobility, skin care, and selected venous abnormalities. Compression may help individual symptoms, although routine stockings for every DVT patient are not recommended by ASH solely to prevent the syndrome. New acute symptoms require separate consideration of recurrent thrombosis.
Apply it
A patient has chronic swelling and pigmentation after DVT but develops sudden additional pain and enlargement. Investigate possible recurrent thrombosis before attributing the abrupt change to the established post-thrombotic syndrome or merely increasing compression.
Common pitfall: Do not use residual ultrasound abnormality alone to diagnose symptomatic post-thrombotic syndrome. Clinical consequences, timing, and alternative explanations remain central to the assessment.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis · ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
53.When is a nonthrombotic iliac vein lesion clinically actionable?
Consider stenting only when significant relevant symptoms, such as quality-of-life-limiting asymmetric edema, venous claudication, or progressive C4–C6 disease, fit outflow obstruction after competing causes are assessed. The VIVA/AVF/AVLS consensus recommends complementary venography and dynamic IVUS, including breath hold and maneuvers increasing intra-abdominal pressure. Fixed lesions are more likely pathological than variable dynamic compression. IVUS thresholds greater than 50% area reduction or greater than 61% diameter stenosis are associated with benefit; intervention below those thresholds is not recommended. These measurements alone do not establish an indication.
Apply it
A symptomatic patient has a fixed lesion exceeding the consensus IVUS threshold after other causes are excluded. This supports consideration of intervention. A variable narrowing or an incidental lesion in an asymptomatic patient does not warrant the same decision.
Common pitfall: Do not substitute CT narrowing, a single IVUS measurement, or a threshold alone for clinical selection. Permanent stenting requires a credible anticipated benefit.
54.How should pelvic symptoms and extra-pelvic varices be linked?
Pelvic venous disorders can involve reflux, obstruction, or both, with presentations including pelvic pain, vulvar varices, and pelvic-origin leg varices. Pelvic pain has many nonvenous causes, so venous anatomy must be correlated with the symptom pattern and competing diagnoses. Similarly, pelvic-origin varices do not automatically require embolisation of every dilated pelvic vein. Assessment should identify the symptomatic territory and mechanism before selecting local varix treatment, embolisation, outflow treatment, or another management pathway appropriate to the individual presentation.
Apply it
A patient has vulvar varices without chronic pelvic pain. Investigate the relevant venous connections and local symptoms rather than assuming that dilated pelvic veins mandate the same treatment used for a patient with disabling pelvic pain.
Common pitfall: Do not diagnose venous pelvic pain from dilated veins alone. Symptom correlation and assessment of competing causes are essential before invasive treatment.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
55.When should effort-related arm swelling raise concern for axillosubclavian thrombosis?
Acute arm swelling, pain, cyanosis, or prominent collateral veins after strenuous or repetitive upper-limb activity can indicate axillosubclavian thrombosis associated with thoracic outlet compression. This differs from catheter-associated upper-extremity DVT and requires attention to both thrombosis and the underlying mechanical setting. Ultrasound is an initial investigation, but central segments may be difficult to assess fully. Persistent clinical suspicion after an inconclusive examination warrants further evaluation rather than reassurance based on incomplete visualisation of the subclavian vein.
Apply it
A young athlete develops a swollen, bluish dominant arm after intensive overhead exercise. Arrange prompt evaluation for axillosubclavian thrombosis and possible thoracic outlet involvement rather than treating the episode as an uncomplicated muscle strain.
Common pitfall: Do not exclude central upper-extremity thrombosis because a technically limited ultrasound is negative. Clavicular anatomy can restrict direct assessment of important venous segments.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
56.What makes phlegmasia a limb-threatening emergency?
Extensive venous thrombosis can obstruct outflow so severely that massive edema compromises microcirculation and eventually arterial inflow. Severe pain, tense swelling, cyanosis, and evolving neurological or perfusion abnormalities suggest phlegmasia rather than routine uncomplicated DVT. This requires urgent vascular assessment, anticoagulation when appropriate, supportive measures, and consideration of thrombus-removal treatment. The presence of a venous cause does not make ischemic signs benign. Rapid progression can threaten both the limb and the patient's systemic condition.
Apply it
A patient with extensive iliofemoral thrombosis develops a tense blue leg, escalating pain, and reduced sensation. Activate urgent vascular management rather than scheduling routine outpatient anticoagulation follow-up for an otherwise stable proximal DVT.
Common pitfall: Do not reserve concern about ischemia for primary arterial occlusion. Severe venous outflow obstruction can secondarily impair arterial perfusion and threaten the limb.
ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
57.How should new sensory symptoms after ablation be interpreted?
New numbness, tingling, burning, or altered sensation after a venous procedure may reflect injury to an adjacent sensory nerve. Distribution, onset, severity, motor findings, and progression help distinguish a local sensory complication from a broader neurological or limb-threatening problem. Distal saphenous anatomy deserves particular attention after thermal treatment. The clinician should document the deficit, assess for associated complications, and arrange appropriate follow-up. Symptoms should not be dismissed solely because the treated vein is successfully closed.
Apply it
After distal small saphenous treatment, a patient reports lateral-foot numbness. Map the sensory change and assess the limb, recognising the nearby sural nerve relationship while checking for findings that would demand more urgent evaluation.
Common pitfall: Do not label every postoperative sensory complaint as harmless bruising. Anatomical distribution and associated neurological or perfusion findings should guide the response.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
58.How do ARTE classification and symptoms determine surveillance and treatment?
Ablation-related thrombus extension class I reaches the superficial-deep junction without deep-lumen extension; class II extends into less than 50% of the deep lumen; class III occupies more than 50% without complete occlusion; class IV is occlusive deep thrombosis. SVS/AVF/AVLS recommends anticoagulation for symptomatic ARTE and asymptomatic ARTE III–IV, generally favoring a direct oral anticoagulant, with treatment continued until retraction. Routine early duplex is discouraged after thermal ablation in asymptomatic average-risk patients. Symptomatic patients and asymptomatic high-risk patients need early duplex; after nonthermal ablation, early duplex may be performed in asymptomatic average-risk patients.
Apply it
New swelling after ablation warrants early duplex. An asymptomatic finding occupying most of the adjacent deep lumen is ARTE III and warrants anticoagulation rather than observation based solely on the absence of symptoms.
Common pitfall: Do not apply the recommendation against routine scanning in asymptomatic average-risk thermal patients to symptomatic patients, high-risk patients, or every nonthermal procedure.
2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
59.How can compression cause focal tissue or nerve injury?
Pressure can concentrate over small-radius bony prominences, tendons, or rolled garment edges. Poor fit, inadequate padding, fragile skin, sensory loss, and impaired perfusion increase the risk of focal injury. New pain, numbness, discoloration, or skin breakdown during compression requires prompt reassessment rather than encouragement to tolerate treatment. Inspection must include the device's position and the whole limb, because an otherwise appropriate prescription can become unsafe through application problems or changes in limb volume.
Apply it
A patient with neuropathy develops a pressure mark beneath a rolled stocking near the ankle. Remove the focal constriction, assess skin and perfusion, and revise fitting and monitoring rather than simply replacing it with a tighter garment.
Common pitfall: Do not rely on pain as the only warning sign. Neuropathy can conceal excessive pressure until skin or nerve injury is already developing.
Risks and Contraindications of Medical Compression Treatment — International Consensus Statement
60.When should an ulcer's presumed venous diagnosis be reconsidered and histology obtained?
Atypical location, an irregular raised edge, disproportionate pain, progressive destruction, or failure to improve despite appropriate treatment requires reassessment for arterial, inflammatory, malignant, neuropathic, or mixed disease. The 2024 DGPL venous-ulcer guideline supports early investigation of atypical morphology and biopsy when etiology remains unresolved and healing is absent despite appropriate care (recommendations 10 and 13–14: https://onlinelibrary.wiley.com/doi/10.1111/ddg.15415). The 2025 Pan-Pacific assessment guideline also recommends reviewing the diagnosis when an ulcer fails to show approximately 25–40% healing within 2–4 weeks of best-practice management.
Apply it
An ulcer with adequate documented perfusion enlarges and develops a raised irregular edge despite appropriate compression. Arrange specialist assessment and histological evaluation rather than delaying investigation for another sequence of dressing changes.
Common pitfall: Do not let genuine coexisting reflux explain every wound feature. An atypical lesion can require early biopsy without waiting for a routine healing-review interval.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritise Diagnostic evaluation, the largest domain: calculate ABI correctly, recognise noncompressibility, interpret duplex and dynamic tests, and connect pretest probability to the next diagnostic step.
- Separate anatomical findings from symptom attribution. Reflux, iliac compression, residual thrombus, and dilated pelvic veins each require clinical interpretation before treatment.
- Link mechanisms to decisions: calf-pump function, lymph transport, coagulation regulation, ultrasound settings, sclerosant injury, and vascular-anomaly flow classification.
- Practise compression decisions using arterial perfusion, skin condition, sensation, device fit, and the distinction between sustained stockings and specialist-selected alternatives.
- Distinguish VTE prophylaxis, acute anticoagulant initiation, primary treatment, secondary prevention, thrombus removal, and filter placement.
- Recognise urgent departures from routine care: phlegmasia, anaphylaxis, anesthetic toxicity, active varicose bleeding, postprocedural thrombosis, and compression-related injury.
- Use the complete official outline to extend this selective guide into detailed pelvic classification, venous tumors and aneurysms, reconstruction, compression syndromes, and other listed investigations and procedures.
A practical preparation plan
1. Build a blueprint-based study map
Use the 2025-effective outline as the full checklist. Allocate study time approximately 21% to Basic science, 32% to Diagnostic evaluation, 28% to practice knowledge and skills, and 19% to Clinical management. Mark topics outside these 60 concepts for additional study.
2. Practise diagnostic sequences
Work through intermediate- and high-probability DVT pathways, proximal versus whole-leg ultrasound, ABI calculations, noncompressible ankle arteries, reflux thresholds, dynamic venous tests, and indications for proximal or lymphatic imaging. State what each result establishes and what remains unresolved.
3. Connect each intervention to its target
For compression, ablation, phlebectomy, sclerotherapy, anticoagulation, thrombus removal, stenting, malformation treatment, and decongestive therapy, identify the mechanism treated, selection criteria, important limitations, and complications requiring action.
4. Use the questions as explanation drills
Complete the 20 MCQs before reading their explanations. For each answer, identify the decisive clinical cue and explain why each alternative is less appropriate. Track errors by domain and reasoning problem rather than treating the score as a pass prediction.
5. Revisit decisions through active recall
Use the flashcards to reconstruct mechanisms and boundaries without looking at the answer. Add brief contrasting cases, such as healed versus active ulceration, incidental versus symptomatic iliac compression, and persistent post-thrombotic symptoms versus new acute deterioration.
6. Complete an integrated review
Revisit unresolved outline topics and practise cases that combine diagnosis, treatment selection, and complication recognition. Use the format FAQs for examination arrangements.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABVLM — How to Prepare
- ABVLM — Applicant FAQs
- ABVLM Exam Content Outline Effective 2025
- ABVLM Certification Candidate Handbook — Revised December 2025
- ABVLM — Eligibility and Fees
- Venous & Lymphatic Medicine Certification Exam Content Summary — November 2016
- ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
- NHGRI — About Factor V Leiden Thrombophilia
- Asclera (polidocanol) Prescribing Information — Revised January 2025
- International Society of Lymphology — 2023 Consensus Document
- 2024 ACC/AHA Multisociety Guideline for Lower Extremity Peripheral Artery Disease
- IAC Standards and Guidelines for Vascular Testing Accreditation — August 3, 2026
- 2023 SVS/AVF/AVLS Varicose Vein Clinical Practice Guidelines — Part II
- ASH — Diagnosis of Venous Thromboembolism: Guideline Teaching Slides
- ASH VTE Guidelines — Treatment of DVT and PE
- ASH — Treatment of Deep Vein Thrombosis and Pulmonary Embolism: Guideline Teaching Slides
- 2024 VIVA/AVF/AVLS Consensus Statement on Nonthrombotic Iliac Vein Lesions
- Risks and Contraindications of Medical Compression Treatment — International Consensus Statement
- Early Versus Deferred Endovenous Ablation in Venous Ulceration — EVRA RCT
- ESVS 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
- ABVLM Exam Calendar & Deadlines | Venous & Lymphatic Medicine
- ABVLM%2BCandidate%2BHandbook%2BJanuary%2B2026.%2BV2.pdf
- NIVL-Management-Consensus.pdf
- venous%20leg%20ulcer%20assessment%20section-2025.pdf
- ISSVAUpdatedflowdiagram_03152025_copyright_3.21.25.pdf
- local-anesthetic-systemic-toxicity-rgb.pdf
- Local Anesthetic Systemic Toxicity (LAST): A Problem-Based Learning Discussion
- WAO-Anaphylaxis-2020.pdf
- 022512s047lbl.pdf
- 2022_esvs_guidelines_mvc.pdf
- 6.-Risks-and-contraindications-of-medical-compression-treatment-A-critical-reappraisal.-An-international-consensus-statement.pdf
- Client Challenge
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.